{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45","upperLimit":"72","value":"59"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"description":"Overall survival is defined from the date of registration to date of death from any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 3 cycles (1 cycle = 21 days) of neoadjuvant chemotherapy (800 mg/m\\^2 of gemcitabine IV and 80 mg/m\\^2 of Paclitaxel IV on days 1 and 8 and Carboplatin IV on day 1), TURBT within 4-8 weeks of chemotherapy, option of proceeding with immediate cystectomy or observation.","id":"OG000","title":"Gemcitabine, Paclitaxel, Carboplatin Followed by Surgery"}],"paramType":"NUMBER","populationDescription":"All eligible patients who started treatment were included in the analysis","reportingStatus":"POSTED","timeFrame":"0-2 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}